Molecular modelling of the human cytochrome P450 isoform CYP2A6 and investigations of CYP2A substrate selectivity

Toxicology

Volumn 133, Issue 1, 1999, Pages 1-33

  Lewis, D F V ^a   Dickins, M ^b   Lake, B G ^c   Eddershaw, P J ^b   Tarbit, M H ^b   Goldfarb, P S ^a  

^a UNIVERSITY OF SURREY   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

^c BIBRA INTERNATIONAL   (United Kingdom)

Author keywords

Coumarin 7 hydroxylase; CYP2A6; Molecular modelling; Substrate selectivity

Indexed keywords

3,5 DIMETHYL 2 (3 PYRIDYL) 4 THIAZOLIDINONE; AFLATOXIN B1; COTININE; COUMARIN; CYTOCHROME P450; FADROZOLE; LOSIGAMONE; NICOTINE;

CONTROLLED STUDY; DEMETHYLATION; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME SPECIFICITY; ENZYME STRUCTURE; HYDROXYLATION; MOLECULAR MODEL; NONHUMAN; OXIDATION; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION;

RUMEX;

EID: 0032957738     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-483X(98)00149-8     Document Type: Article

References (81)

1. Bourrie M., Meunier V., Berger Y., Fabre G. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J. Pharmacol. Exp. Ther. 277:1996;321-332.
2. Burkhart B.A., Harada N., Negishi M. Sexual dimorphism of testosterone 15α-hydroxylase mRNA levels in mouse liver. J. Biol. Chem. 260:1985;15357-15361.
3. Chang T.K.H., Waxman D.J. The CYP2A subfamily. Ioannides C. Cytochromes P450-Metabolic and Toxicological Aspects. 1996;99-134 CRC Press, Boca Raton, FL.
4. Chothia C. Structural invariants in protein folding. Nature. 254:1975;304-308.
5. Creighton T.E. Proteins: Structures and Molecular Properties. 1993;W.H. Freeman, New York.
6. Ding X., Peng H.-M., Coon M.J. Heterologous expression and structure-function analysis of CYP2A10 and CYP2A11, which differ in only eight amino acids but have strikingly different activities toward testosterone and coumarin. Lechner M.C. Cytochrome P450, 8th International Conference. 1994;885-888 Libbey, Paris.
7. Ding S., Lake B.G., Friedberg T., Wolf C.R. Expression and alternative splicing of the cytochrome P-450 CYP2A7. Biochem. J. 306:1995;161-166.
8. Draper A.J., Madan A., Parkinson A. Inhibition of coumarin 7-hydroxylase activity in human liver microsomes. Arch. Biochem. Biophys. 341:1997;47-61.
9. Fauchere J.L., Pliska V. Hydrophobic parameters (π) of amino acid side-chains from the partitioning of N-acetyl amino acid amides. Eur. J. Med. Chem. 18:1983;369-375.
10. Fentem J.H., Fry J.R. Metabolism of coumarin by rat, gerbil and human liver microsomes. Xenobiotica. 22:1992;357-367.
11. Fernandez-Salguero P., Hoffman S.M.G., Cholerton S., Mohrenweiser H., Raunio H., Rautio A., Pelkonen O., Huang J.-D., Evans W.E., Idle J.R., Gonzalez F.J. A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. Am. J. Hum. Genet. 57:1995;651-660.
12. Forrester L.M., Henderson C.J., Glancey M.J., Back D.J., Park B.K., Ball S.E., Kitteringham N.R., McLaren A.W., Miles J.S., Skett P., Wolf C.R. Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics. Biochem. J. 281:1992;359-368.
13. Gonzalez F.J., Gelboin H.V. Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. Drug Metab. Rev. 26:1994;165-183.
14. Gonzalez F.J., Matsunaga T., Nagata K. Structure and regulation of P450s in the rat P450IIA gene subfamily. Drug Metab. Rev. 20:1989;827-837.
15. Gonzalez F.J. Human cytochromes P450: problems and prospects. Trends Pharm. Sci. 13:1992;346-352.
16. Gotoh O. Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. J. Biol. Chem. 267:1992;83-90.
17. Guengerich F.P. Human cytochrome P450 enzymes. Ortiz de Montellano P.R. Cytochrome P450. 1995;473-535 Plenum, New York.
18. Gullsten H., Agundez J.A.G., Benitez J., Laara E., Ladero J.M., Diaz-Rubio M., Fernandez-Salguero P., Gonzalez F., Rautio A., Pelkonen O., Raunio H. CYP2A6 gene polymorphism and risk of liver cancer and cirrhosis. Pharmacogenetics. 7:1997;247-250.
19. Hadidi H., Zahlsen K., Idle J.R., Cholerton S. A single amino acid substitution (Leu160His) in cytochrome P450 2A6 causes switching from 7-hydroxylation to 3-hydroxylation of coumarin. Food Chem. Toxicol. 35:1997;903-907.
20. Hanioka N., Gonzalez F.J., Lindberg N.A., Liu G., Gelboin H.V., Korzekwa K.R. Site-directed mutagenesis of cytochrome P450s CYP2A1 and CYP2A2: influence of the distal helix on the kinetics of testosterone hydroxylation. Biochemistry. 31:1992;3364-3370.
21. Hong J.-Y., Yang C.S., Lee M.-J., Wang Y.-Y., Wang W.-Q. Role of cytochromes P450 in the metabolism of methyl tert-butyl ether in human livers. Proceedings of the 11th International Symposium on Microsome and Drug Oxidations, University of California, Los Angeles, July 21-24. 1996;174.
22. Honkakoski P., Negishi M. The structure, function and regulation of cytochrome P4502A enzymes. Drug Metab. Rev. 29:1997;977-996.
23. 7α): role of residue-209 in determining steroid-cytochrome P450 interaction. Biochem. J. 291:1993;569-573.
24. coh to a novel corticosterone 15α-hydroxylase and modeling steroid-binding orientation in the substrate pocket. J. Biol. Chem. 268:1993;759-762.
25. Iwasaki M., Darden T.A., Parker C.E., Tomer K.B., Pedersen L.G., Negishi M. Inherent versatility of P450 oxygenase. J. Biol. Chem. 269:1994;9079-9083.
26. Iwasaki M., Davis D.G., Darden T.A., Pedersen L.G., Negishi M. Multiple steroid-binding orientations: alteration of regiospecificity of dehydroepiandrosterone 2- and 7-hydroxylase activities of cytochrome P450 2a5 by mutation of residue 209. Biochem. J. 306:1995;29-33.
27. Jones B.C., Tyman C.A., Smith D.A. The O-demethylation of 4-nitroanisole is mediated by CYP2A6 and CYP2E1 in human liver microsomes. Proceedings of the 11th International Symposium on Microsome and Drug Oxidations, University of California, Los Angeles, July 21-24. 1996;175.
28. Jones B.C., Tyman C.A., Smith D.A. Identification of the cytochrome P450 isoforms involved in the O-demethylation of 4-nitroanisole in human liver microsomes. Xenobiotica. 27:1997;1025-1037.
29. coh). J. Biol. Chem. 266:1991;16431-16435.
30. coh by mutation of glycine-207 to proline: spin equilibrium, enzyme kinetics and heat sensitivity. Biochem. J. 294:1993;31-34.
31. Kinonen T., Padanen M., Gynther J., Poso A., Jarvinen T., Alhava E., Juvonen R.O. Competitive inhibition of coumarin 7-hydroxylation by pilocarpine and its interaction with mouse CYP245 and human CYP2A6. Br. J. Pharmacol. 116:1995a;2625-2630.
32. Kinonen T., Juvonen R.O., Alhava E., Pasanen M. The inhibition of CYP enzymes in mouse and human liver by pilocarpine. Br. J. Pharmacol. 114:1995b;832-836.
33. Koenigs L.L., Peter R.M., Thompson S.J., Rettie A.E., Trager W.F. Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen. Drug Metab. Dispos. 25:1997;1407-1415.
34. Lake B.G. Coumarin: species differences in metabolism. Proceedings of the 7th International Information Exchange, Lanaken, Belgium, November 16-17, 1995. 1996;33-43 Research Institute for Fragrance Materials, Hackensack, NJ.
35. Lake B.G., Grasso P Comparison of the hepatotoxicity of coumarin in the rat, mouse and Syrian hamster: a dose and time response study. Fund. Appl. Toxicol. 34:1996;105-117.
36. 14C]coumarin in the rat and marmoset. Toxicol. Lett. 45:1989;299-306.
37. 14C]coumarin to polar and covalently bound products by hepatic microsomes from the rat, Syrian hamster, gerbil and humans. Food Chem. Toxicol. 30:1992;105-115.
38. Lake B.G., Osborne D.J., Walters D.G., Price R.J. Identification of o-hydroxyphenylacetaldehyde as a major metabolise of coumarin in rat hepatic microsomes. Food Chem. Toxicol. 30:1992;99-104.
39. Lake B.G., Evans J.G., Lewis D.F.V., Price R.J. Studies on the acute effects of coumarin and some coumarin derivatives in the rat. Food Chem. Toxicol. 32:1994;357-363.
40. Lewis D.F.V. Cytochromes P450: Structure, Function and Mechanism. 1996;Taylor and Francis, London.
41. Lewis D.F.V. The CYP2 family: models mutants and interactions. Xenobiotica. 28:1998;617-661.
42. Lewis D.F.V., Lake B.G. Molecular modelling of members of the P4502A subfamily: application to studies of enzyme specificity. Xenobiotica. 25:1995;585-598.
43. Lewis D.F.V., Brantom P.G., Ioannides C., Walker R., Parke D.V. Nitrosamine carcinogenesis: rodent assays, quantitative structure-activity relationships, and human risk assessment. Drug Metab. Rev. 29:1997;1055-1078.
44. BM-3 haem domain complexed with the fatty acid substrate, palmitoleic acid. Nat. Struct. Biol. 4:1997;140-146.
45. coh substrate specificity by mutation of a single amino-acid residue. Nature. 339:1989;632-634.
46. 15α gene. J. Biol. Chem. 264:1989;6465-6471.
47. coh. Pharmacogenetics. 2:1992;32-37.
48. Liu C, Zhuo X., Gonzalez F.J., Ding X. Baculovirus-mediated expression and characterization of rat CYP2A3 and human CYP2A6: role in metabolic activation of nasal toxicants. Mol. Pharmacol. 50:1996;781-788.
49. Lovell, D.P., van Iersel, M., Walters, D.G., Price, R.J., Lake, B.G., 1998. Genetic variation in the metabolism of coumarin in mouse liver. Pharmacogenetics 8 (in press).
50. Maenpaa J., Sigusch H., Raunio H., Syngelma T., Vuorela P., Vuorela H., Pelkonen O. Differential inhibition of coumarin 7-hydroxylase activity in mouse and human liver microsomes. Biochem. Pharmacol. 45:1993;1035-1042.
51. Messina E.S., Tyndale R.F., Sellers E.M. Nicotine metabolism by human liver microsomes. Proceedings of the 11th International Symposium on Microsomes and Drug Oxidations, University of California, Los Angeles, July 21-24. 1996;17.
52. Miles J.S., McLaren A.W., Forrester L.M., Glancey M.J., Lang M.A., Wolf C.R. Identification of the human liver cytochrome P450 responsible for coumarin 7-hydroxylase activity. Biochem. J. 267:1990;365-371.
53. Nakajima M., Yamamoto T., Nunoya K.-I., Yokoi T., Nagashima K., Inoue K., Funae Y., Shimada N., Kamataki T., Kuroiwa Y. Characterization of CYP2A6 involved in 3′-hydroxylation of cotinine in human liver microsomes. J. Pharmacol. Exp. Ther. 277:1996;1010-1015.
54. Negishi M., Iwasaki M., Juvonen R.O., Sueyoshi T., Darden T.A., Pedersen L.G. Structural flexibility and functional versatility of cytochrome P450 and rapid evolution. Mut. Res. 350:1996;43-50.
55. Negishi M., Uno T., Darden T.A., Sueyoshi T., Pedersen L.G. Structural flexibility and functional versatility of mammalian P450 enzymes. FASEB J. 10:1996;683-689.
56. Nelson D.R., Koymans L., Kamataki T., Stegeman J.J., Feyereisen R., Waxman D.J., Waterman M.R., Gotoh O., Coon M.J., Estabrook R.W., Gunsalus I.C., Nebert D.W. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics. 6:1996;1-42.
57. Nunoya K.-I., Yokoi T., Kimura K., Kodama T., Funayama M., Inoue K., Nagashima K., Funae Y., Shimada N., Green C., Kamataki T. (+)-cis-3,5-Dimethyl-2-(3-pyridyl) thiazolidin-4-one hydrochloride (SM-12502) as a novel substrate for cytochrome P450 2A6 in human liver microsomes. J. Pharmacol. Exp. Ther. 277:1996;768-774.
58. Ono S., Hatanaka T., Hotta H., Satoh T., Gonzalez F.J., Tsutsu M. Specificity of substrate and inhibitor probes for cytochrome P450s: evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotica. 26:1996;681-693.
59. Pearce R., Greenway D., Parkinson A. Species differences and interindividual variation in liver microsomal cytochrome P4502A enzymes: effect on coumarin, dicumarol and testosterone oxidation. Arch. Biochem. Biophys. 298:1992;211-225.
60. Pelkonen O., Raunio H. Individual expression of carcinogen-metabolizing enzymes: cytochrome P4502A. J. Occup. Environ. Med. 37:1995;19-23.
61. 1 with cytochrome P450 2A5 and its mutants: correlation with metabolic activation and toxicity. Chem. Res. Toxicol. 10:1997;85-90.
62. Raunio H., Pelkonen O. Cancer genetics: genetic factors in the activation and inactivation of chemical carcinogens. Ioannides C., Lewis D.F.V. Drugs, Diet and Disease. 1995;229-258 Ellis Horwood, Chichester.
63. Rautio A., Gullsten H., Pelkonen O., Raunio H. CYP2A6 polymorphism. Proceedings of the 11th International Symposium on Microsomes and Drug Oxidations, University of California, Los Angeles, July 21-24. 1996;146.
64. BM-3, a prototype for microsomal P450s. Science. 261:1993;731-736.
65. Reigh G., McMahon H., Ishizaki M., Ohara T., Shimane K., Esumi Y., Green C., Tyson C., Ninomiya S.-I. Cytochrome P450 species involved in the metabolism of quinoline. Carcinogenesis. 17:1996;1989-1996.
66. Rendic S., Di Carlo F.J. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers and inhibitors. Drug Metab. Rev. 29:1997;413-580.
67. Rossman M.A. Hydrophilicity of polar amino acid sidechains is markedly reduced by flanking peptide bonds. J. Mol. Biol. 200:1988;513-522.
68. Salonpaa P., Pelkonen O., Kojo A., Pasanen M., Negishi M., Raunio H. Cytochrome P4502A5 expression and inducibility by phenobarbital is modulated by cAMP in mouse primary hepatocytes. Biochem. Biophys. Res. Commun. 20S:1994;631-637.
69. Shimada T., Yamazaki H., Mimura M., Inui Y., Guengerich F.P. Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals. J. Pharmacol. Exp. Ther. 270:1994;414-423.
70. Shimada T., Yamazaki H., Guengerich F.P. Ethnic-related differences in coumarin 7-hydroxylation activities catalyzed by cytochrome P4502A6 in liver microsomes of Japanese and Caucasian populations. Xenobiotica. 26:1996;395-403.
71. Spracklin D.K., Thummel K.E., Kharasch E.D. Human reductive halothane metabolism in vitro is catalyzed by cytochrome P450 2A6 and 3A4. Drug Metab. Dispos. 24:1996;976-983.
72. 15α) in renal microsomes of female mice. Biochemistry. 25:1986;4913-4918.
73. 15α) in liver and kidney of male mice by androgen. J. Biol. Chem. 263:1988;4166-4171.
74. Steensma A., Beamand J.A., Walters D.G., Price R.J., Lake B.G. Metabolism of coumarin and 7-ethoxycoumarin by rat, mouse, guinea pig, cynomolgus monkey and human precision-cut liver slices. Xenobiotica. 24:1994;893-907.
75. Torchin C.D., McNeilly P.J., Kapetanovic I.M., Strong J.M., Kupferberg H.J. Stereoselective metabolism of a new anticonvulsant drug candidate, losigamone, by human liver microsomes. Drug Metab. Dispos. 24:1996;1002-1008.
76. 14C]coumarin by human liver microsomes. Xenobiotica. 24:1994;795-803.
77. van Iersel M., Walters D.G., Price R.J., Lovell D.P., Lake B.G. Sex and strain differences in mouse hepatic microsomal coumarin 7-hydroxylase activity. Food Chem. Toxicol. 32:1994;387-390.
78. Walter B.A., Hundal J.S. In vitro metabolism of fadrozole (CGS 16949A) in human microsomes and human cell lines expressing a single P450 isozyme. Proceedings of the 6th North American ISSX Meeting, Rayleigh, NC, October 23-27. 6:1994 p. 187.
79. Yamano S., Tatsuno J., Gonzalez F.J. The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry. 29:1990;1322-1329.
80. Yamazaki H., Inui Y., Yun C., Guengerich F.P., Shimida T. Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. Carcinogenesis. 13:1992;1789-1794.
81. Yokoi T., Kamataki T. Genetic polymorphism of drug metabolizing enzymes: new mutations in CYP2D6 and CYP2A6 genes in Japanese. Pharm. Res. 15:1998;517-524.